EK
Insider
Eliyahu Sharon Kalif
EVP, Chief Financial OfficerEliyahu Sharon Kalif (EVP, Chief Financial Officer) filed 3 Form 4 reports in the trailing twelve months (0 purchases, 3 sales, 1 filed past the two-business-day deadline), most often in Teva Pharmaceutical Industries Limited (TEVA). The largest single filing was $11.6M of TEVA (345,810 sh × $33.64, as filed), executed Feb 26.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
3
0 buys · 3 sells · 1 late
Median delay
–
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$20.7M
shares × price, as filed
Last traded
Jun 11
Filed Jun 16
Median ADV $196.1M across their filed names
Open performance→Volume by month
Buys $0
Sells $22.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
3 filings
Sector per market data · by filing · past 12 months
Most traded names
TEVARecent filings
TEVASALE
Teva Pharmaceutical Industries Limited
View filing →
$3.6M106,563 sh × $34.10
Exec Jun 11
Filed Jun 16 · 5:30 PM ET † TEVASALE Teva Pharmaceutical Industries Limited View filing → $5.5M
153,251 sh × $35.61
Exec May 14
Filed May 18 · 5:30 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $11.6M
345,810 sh × $33.64
Exec Feb 26
Filed Mar 2 · 5:30 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $953K
55,775 sh × $17.08
Exec Jun 12 2025
Filed Jun 16 2025 · 5:30 PM ET TEVASALE Teva Pharmaceutical Industries Limited View filing → $904K
55,750 sh × $16.21
Exec Feb 28 2025
Filed Mar 4 2025 · 5:30 PM ET